Study results presented at this year’s American Academy of Allergy Asthma & Immunology annual meeting displayed dupilumab efficacy in children aged 6 months to 5 years who had atopic dermatitis (AD).
Atopic comorbidities did not affect outcomes among pediatric patients with atopic dermatitis (AD) who were on a treatment regimen of dupilumab (Dupixent) plus topical corticosteroids (TCS), according to data presented at this year’s American Academy of Allergy Asthma & Immunology meeting in San Antonio.
Among children aged 6 months to 5 years living with moderate to severe AD, clinical outcomes following the combination treatment were evaluated for potential influence from 3 caregiver-reported type 2 comorbidities—asthma, allergic rhinitis, and food allergies—and compared between participants who did and did not have these comorbidities.
The LIBERTY AD PRESCHOOL study population was randomized 1:1 to dupilumab every 4 weeks (n = 83), with dose based on baseline weight (≥5 to <15 kg, 200 mg; ≥15 to <30 kg, 300 mg), or placebo (n = 79), both plus TCS. Safety end points considered were treatment-emergent adverse events (TEAEs), serious TEAEs, TEAE leading to discontinuation, and severe TEAE, and Investigator’s Global Assessment (IGA) score (0 = clear, 4 = severe AD) and Eczema Area and Severity Index gauged symptom improvement after 16 weeks. Disease severity and comorbidity history were similar between the groups at baseline.
Among the patients who did or did not have comorbid asthma, allergic rhinitis, or food allergies, the following results were seen at week 16 among patients receiving the combination of dupilumab plus TCS:
Stark differences were seen when comparing the above with results seen among the patients receiving placebo plus TCS:
“Overall safety was consistent with the known dupilumab safety profile,” the study authors wrote, “with dupilumab with concomitant TCS being equally efficacious in improving AD signs in children ages 6 months to 5 years with and without a history of atopic comorbidities.”
Illustrating this point, they also presented their TEAE data:
Further, overall rates of TEAEs were consistently lower in the combination vs placebo group regardless of comorbidity presence:
Reference
Boguniewicz M, Sher LD, Paller AS, Chen Z, Shah P, Marco AR. Dupilumab efficacy in children with atopic dermatitis aged 6 months to 5 years with and without atopic comorbidities. Presented at: American Academy of Allergy Asthma & Immunology Annual Meeting; February 24-27, 2023; San Antonio, TX. https://bit.ly/3J3pA3R
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen